Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-06-13 Legal Proceedings Report
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Litigation Update 2 pages 171.1KB
Legal Proceedings Report Classification · 95% confidence The document is a litigation update announcing new class action proceedings and settlement details related to legal matters involving the company Mesoblast. It discusses ongoing and resolved lawsuits, insurance coverage, and court hearing dates. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The content focuses solely on legal proceedings and company responses to litigation. Therefore, the document fits the category of Legal Proceedings Report (LTR). The document length is sufficient and contains substantive information about legal matters, not just an announcement or summary.
2022-06-13 English
Mesoblast to Host KOL Event on Chronic Low Back Pain 3 pages 166.7KB
Investor Presentation Classification · 95% confidence The document is a press release announcing a webinar event hosted by Mesoblast Limited for investors and analysts. It focuses on presentations by key opinion leaders and company executives about clinical trial outcomes and the regulatory pathway for a product. There are no financial statements, detailed financial analysis, or regulatory filings included. The document is promotional and informational about an upcoming investor event rather than a formal financial report or regulatory filing. It does not contain quarterly or annual financial results, audit information, or management discussion of financial performance. The content aligns with an Investor Presentation (IP) as it is aimed at investors and analysts, providing detailed information on clinical trial results, company strategy, and product development. The document length (over 10,000 characters) supports it being more than a brief announcement, and it includes detailed speaker biographies and company background, typical of investor presentations.
2022-06-08 English
6-K
Regulatory Filings
2022-06-03 English
6-K
Regulatory Filings
2022-06-03 English
Third Quarter Financial Results on Form 6-K 96 pages 596.2KB
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the U.S. SEC by Mesoblast Limited, a foreign private issuer. It covers the three and nine months ended March 31, 2022, and includes unaudited financial statements, management's discussion and analysis, risk factors, and signatures. The presence of detailed financial statements such as the consolidated income statement, statement of comprehensive income, and changes in equity, along with management discussion, indicates this is a comprehensive interim or quarterly report rather than a brief announcement or certification. Form 6-K is typically used by foreign private issuers to report interim financial information and other material information between annual reports. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). The document length (15,000 characters) and content confirm it is a full report, not just an announcement or certification.
2022-05-31 English
MSB Q3 Financial Results and Operational Highlights 9 pages 348.0KB
Interim / Quarterly Report Classification · 95% confidence The document provides detailed financial results and operational highlights for the period ended March 31, 2022, including revenue, cash usage, expenses, and loss after tax. It also includes extensive discussion of clinical trial updates, regulatory interactions, and management changes such as new board and executive appointments. The presence of comprehensive financial data for a specific fiscal quarter (third quarter FY2022) and operational details indicates this is a comprehensive interim or quarterly report rather than a brief earnings release or announcement. The document length is substantial (15,000 characters), and it contains actual financial statements and analysis, not just references or links to reports. There is also a mention of a conference call webcast, but the document itself is not a transcript. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2022-05-31 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.